KRAS and lung carcinoma: Miriam Molina-Arcas from the Crick Institute in London, Great Britain, talked about the impact of the KRAS oncogene signaling on the TME with focus on lung cancer, KRAS as the most common driver oncogene with a frequency of 32% in this disease.